Skip to main content

Table 2 Genotypes of UGT1A and DPYD in mCRC patients

From: Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

Genotypes No. of patients %
UGT1A1*6
 G/G 431 65.2%
 G/A 198 30.0%
 A/A 32 4.8%
UGT1A1*27
 C/C 535 98.2%
 C/A 10 1.8%
UGT1A1*28
 TA6/TA6 501 75.8%
 TA6/TA7 152 23.0%
 TA7/TA7 8 1.2%
UGT1A7
UGT1A7*1/*1 196 36.0%
UGT1A7*1/*2 103 18.9%
UGT1A7*1/*3 131 24.0%
UGT1A7*2/*2 31 5.7%
UGT1A7*2/*3 53 9.7%
UGT1A7*3/*3 31 5.7%
UGT1A9*22
 T9/T9 99 18.2%
 T9/T10 442 81.1%
 T10/T10 4 0.7%
DPYD*5
 A/A 256 51.6%
 A/G 199 40.1%
 G/G 41 8.3%
DPYD*2A
 G/G 495 99.8%
 G/A 1 0.2%
DPYD c.1896 T > C
 T/T 395 79.6%
 T/C 96 19.4%
 C/C 5 1.0%